hiv-aids

New diagnoses falling, with 20% fewer cases in Catalonia in 2021 than previous year

Catalan researchers among team studying three infected people who show no signs of virus despite not taking antiretroviral drugs

As AIDS Day is commemorated globally, we review the epidemic’s evolution to the advent of PrEP, the HIV prevention pill

BCN PrEP·Point follows up with individuals who take the medication “on their own accord” and aims to help research its effects

A clinical trial of a vaccine has proved, for the first time ever, that the immune system of those infected with AIDS can be re-educated in order to control the virus for long periods of time and without taking anti-retroviral drugs. In particular, 5 of the 13 patients whom participated in the trial and stopped their treatment achieved control of the virus for 5, 13, 17, 20 and 27 weeks respectively. The research, which is still ongoing, is being developed in different hospitals in Barcelona and Badalona and is directed by the IrsiCaixa AIDS Research Institute, a leading centre for research into the eradication of HIV/AIDS and related diseases, and the Fight AIDS Foundation, a non-profit organisation that is dedicated to healthcare, research and education in the field of HIV/AIDS, created by Doctor Bonaventura Clotet in 1992.

Every day in every hospital in the world blood is needed. The only way to get it is from donations, since blood cannot be created artificially. Each altruist action may serve to help three different patients. In Catalonia, for the system to work optimally 1,000 donations a day would be needed but the average donation figure is lower. Everyone can donate if they weigh over 50kg, since a donation is 450ml of blood and a minimum weight is required. Men can do it four times a year and women three times. There are now various mobile units that travel throughout Catalonia to make donating more accessible to donors.

At the HIV Vaccine World Congress, which is taking place in Barcelona between the 7^th and 10^th October, Catalan researchers presented a vaccine prototype that has proven to be effective in clinical studies conducted with mice and monkeys. The vaccine stimulates the creation of antibodies and attacks infected cells. The prototype has been created by the Catalan programme to develop a vaccine against HIV, HIVACAT. According to the programme’s Scientific Director, Christian Brander, the vaccine could eventually also be used as a therapeutic treatment.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

An international study with the participation of the Hospital Clínic IDIBAPS, which is a leading research centre at a world level on AIDS/HIV and other common diseases, has proved that an anti-retroviral treatment carried out just after the infection delays the damage to the patient’s immune system and reduces the risk of transmission. The results of clinical tests on 366 infected individuals confirmed that the sooner and longer an initial anti-retroviral treatment is applied, the later the life-long treatments have to start. However, despite the results, researchers insist that is still too soon to change the current AIDS/HIV treatment protocols.

The IDIBAPS has opened a new research centre of more than 5,000 m2, where more than 200 researchers split into 23 different research groups will be working. It will focus its work on oncology, neurosciences and cell therapies along with infectious, respiratory, cardiovascular and renal diseases. The new centre has been possible thanks to a donation by the private foundation CELLEX, sponsored by Pere Mir. The new centre is located within the University of Barcelona’s Faculty of Medicine, which is integrated into the prestigious Hospital Clínic. The centre consolidates Catalonia, and in particular Barcelona, as one of Europe’s main biomedical poles.

The scientists working at the HIVACAT project for the development of an effective cure against the HIV virus are hopeful of finding a vaccine in the near future that would stop patients having to be treated for their whole life, actually eradicating the disease. The researchers have tested a first vaccine that has proved effective in reducing the viral load by up to 95%. However, the vaccine effects are only temporary, so researchers will continue the investigation in order to achieve a permanent effect.

This weekend, 14,500 people rocked at the Palau Sant Jordi, in Montjuïc, in a charity concert that brought together the most famous Catalan singers and bands. Singer songwriter Lluís Llach interpreted a poem with former F.C. Barcelona Manager, Pep Guardiola, who finished with the verse: “Everything is to be done, and everything is possible”. 20 more artists participated in the concert, which turned into a cry against AIDS and for the independence of Catalonia.

This world important discovery should open new paths to develop new drugs and to ultimately find a vaccine against HIV/AIDS. The finding has been published in the international journal PLoS Biology. The study has been funded by the Spanish Government, the Catalan Government, La Caixa savings bank, Barcelona’s Hospital Clínic and Esteve Labs.